Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/tacrine-in-alzheimer-s-disease-reply-VPRgrJ8PeT
References (8)
-
K. Davis, L. Thal, E. Gamzu, C. Davis, R. Woolson, S. Gracon, D. Drachman, L. Schneider, P. Whitehouse, T. Hoover, J. Morris, C. Kawas, D. Knopman, N. Earl, Vinod Kumar, R. Doody (1992)
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.The New England journal of medicine, 327 18
-
M. Cho, L. Bero (1994)
Instruments for assessing the quality of drug studies published in the medical literature.JAMA, 272 2
-
K. Rothman (1993)
Conflict of interest. The new McCarthyism in science.JAMA, 269 21
-
M. Winker (1994)
TACRINE FOR ALZHEIMER'S DISEASE : WHICH PATIENT, WHAT DOSE ?JAMA, 271
-
W. Stigelman, P. D. (1986)
Goodman and Gilman's the Pharmacological Basis of TherapeuticsMilitary Medicine, 151
-
W. Rosen, R. Mohs, K. Davis (1984)
A new rating scale for Alzheimer's disease.The American journal of psychiatry, 141 11
-
M. Knapp, D. Knopman, P. Solomon, W. Pendlebury, C. Davis, S. Gracon, J. Apter, Clifford Lazarus, Karen Baker, M. Barnett, B. Baumel, L. Eisner, D. Bennett, C. Forchetti, A. Levin, J. Blass, K. Nolan, E. Gaines, N. Relkin, R. Borison, B. Diamond, G. Celesia, A. Ross, J. Dexter, R. Doody, L. Lipscomb, Kurt Kreiter, E. Duboff, P. Block, D. Marshall, Nancy Westergaard, N. Earl, S. Wyne, Elisabeth Hinman-Smith, M. Farlow, H. Hendrie, Judith Caress, M. Farmer, J. Harper, J. Ferguson, N. Foster, N. Barbas, L. Bluemlein, Douglas Gelb, S. Berent, B. Giordani, M. Greenwald, S. Bergman, L. Roger, A. Groenendyk, M. Wood, C. Jurkowski, I. Katz, Suzanne Doyle, Buster Smith, C. Kellner, H. Bernstein, D. Bachman, S. Deinard, L. Langley, Sarah Bridges, R. Margolin, M. Burger, S. Wiser, C. Crenshaw, J. Morris, E. Rubin, M. Coats, P. Reyes, Catherine Bentz, Lara Doyle, M. Rymer, I. Bettinger, M. Laubinger, C. Sadowsky, Walter Martínez, J. Zúñiga, R. Stone, P. Winner, L. Maté, Carla Lessard, L. Schneider, S. Pawluczyk, Ward Smith, Scott Losk, Linda Marambe, M. Groccia-Ellison, K. Edwards, John Taylor, V. Calabrese, S. Harkins, S. Thein, J. Dewar, G. Williams, C. Drennan, Paul Tuttle, N. Principi, E. Ford, Robert Tyndall, C. Kelley (1994)
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's DiseaseJAMA, 271
-
M. Lawton, E. Brody (1969)
Assessment of older people: self-maintaining and instrumental activities of daily living.The Gerontologist, 9 3
- Publisher
- American Medical Association
- Copyright
- Copyright © 1993 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.1993.03500220034020
- Publisher site
- See Article on Publisher Site
Abstract
In Reply. —Our tacrine study was designed to support preliminary results from a preceding enrichment trial1 and to define dose-response characteristics using doses from 20 to 80 mg/d. The a priori hypothesis (as indicated on page 2525) addressed whether tacrine improves patient response on the Alzheimer's Disease Assessment Scale (ADAS) cognitive and the clinician-rated Clinical Global Impression of Change (CGIC). The ADAS cognitive has been validated in Alzheimer's disease and demonstrated sensitivity to modest drug effects and cognitive deterioration over time.2 However, the clinician-rated CGIC had not been validated in this patient population.3 Therefore, our primary focus on ADAS cognitive reflected uncertainty in use of the CGIC when the study was designed. The sample size was set to provide sufficient power to detect ADAS cognitive effects based on previous studies of tacrine.1 Primary analyses based on "evaluable completers" were most appropriately presented in the original publication.
Journal
JAMA – American Medical Association
Published: Jun 9, 1993